カテゴリ： GlobalData, アメリカ, 企業調査

PTC Therapeutics Inc (PTCT)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：PTC Therapeutics Inc (PTCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012208
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and commercializes orally active small molecule therapeutics that target post transcriptional control. The company’s pipeline products include an orally administered small-molecule targeted at genetic disorders due to a nonsense mutation; an orally active small molecule to reduce the function, activity and amount of BMI1; and an investigational oral therapeutic used for the treatment of spinal muscular atrophy. PTC Therapeutics’ ataluren is in phase 3 for the treatment of nonsense mutation duchenne muscular dystrophy.The company works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.

PTC Therapeutics Inc (PTCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12
Venture Financing 14
PTC Therapeutics Raises US$60 Million In Venture Financing 14
PTC Therapeutics Raises US$2 Million In Venture Financing 16
Ptc Therapeutics Raises US$30 Million In Venture Financing 17
Partnerships 18
PTC Therapeutics Enters into Agreement with University of Pennsylvania 18
Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 19
Dualsystems Biotech Enters Into Agreement With PTC Therapeutics For Drug Profiling 20
PTC Therapeutics Expands Its Collaboration With Parent Project Muscular Dystrophy 21
Licensing Agreements 22
Roche Enters Into Licensing Agreement With PTC Therapeutics And SMA Foundation 22
PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 23
AstraZeneca Enters Into Collaboration And Licensing Agreement With PTC Therapeutics 24
Equity Offering 25
PTC Therapeutics Raises USD125 Million in Public Offering of Shares 25
PTC Therapeutics Completes Public Offering Of Shares For US$126.5 Million 27
PTC Therapeutics Completes IPO For US$144.4 Million 29
Debt Offering 31
PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 31
Acquisition 33
Sanofi May Acquire PTC Therapeutics 33
PTC Therapeutics Inc – Key Competitors 34
PTC Therapeutics Inc – Key Employees 35
PTC Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 38
Financial Announcements 38
Nov 02, 2017: PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 08, 2017: PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 40
May 08, 2017: PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 16, 2017: PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 43
Jan 09, 2017: PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna and Advance its Innovative Pipeline 45
Nov 02, 2016: PTC Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update 46
Aug 04, 2016: PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update 48
May 05, 2016: PTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update 50
Feb 29, 2016: PTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 52
Corporate Communications 54
Jul 24, 2017: PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development 54
Jun 05, 2017: PTC Therapeutics Announces Executive Promotions 55
Apr 10, 2017: PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs 56
Jun 13, 2016: PTC Therapeutics Appoints Dawn Svoronos to Board of Directors 57
Apr 26, 2016: PTC Therapeutics Appoints Dr. Tuyen Ong as Chief Medical Officer 58
Government and Public Interest 59
Feb 08, 2017: PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 59
Feb 12, 2016: PTC Therapeutics Announces Second Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 60
Product News 61
04/15/2016: NICE recommends ataluren for treating Duchenne muscular dystrophy caused by a nonsense mutation 61
03/23/2016: PTC Therapeutics Announces Workforce Reduction as Part of Operating Expense Management Plan 63
03/09/2016: Marathon Pharmaceuticals Announces Nationwide Expanded Access Program for Patients with Duchenne Muscular Dystrophy 64
02/26/2016: PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna (ataluren) 65
Product Approvals 66
Feb 09, 2017: FDA Approves EMFLAZA (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older 66
Aug 10, 2016: FDA Accepts Marathon Pharmaceuticals New Drug Applications for Deflazacort for the Treatment of Duchenne Muscular Dystrophy and Grants Priority Review 67
Jun 14, 2016: Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA 68
Mar 14, 2016: PTC Therapeutics Provides Update on Health Canada Review of Translarna (ataluren) for the Treatment of Duchenne Muscular Dystrophy 69
Feb 23, 2016: PTC Receives Refuse to File Letter from FDA for Translarna (ataluren) 70
Jan 11, 2016: PTC Therapeutics Outlines Business Priorities for the Development and Commercialization of Translarna and Progress of the Company Pipeline 71
Jan 08, 2016: PTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy 72
Clinical Trials 73
Sep 08, 2016: Study Could Herald New Treatment for Muscular Dystrophy 73
Aug 30, 2016: Marathon Pharmaceuticals Announces Neurology Publication of Pivotal Phase 3 Data for Deflazacort for Duchenne Muscular Dystrophy 74
Apr 19, 2016: Marathon Pharmaceuticals Presents Analyses at AAN of a Phase III Clinical Study of Deflazacort in Patients with Duchenne Muscular Dystrophy (DMD) 75
Mar 14, 2016: PTC Therapeutics Announces Presentation of Results from Phase 3 ACT DMD Clinical Trial of Translarna (ataluren) in Patients with Duchenne Muscular Dystrophy at 5th International Congress of Myology 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PTC Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12
PTC Therapeutics Raises US$60 Million In Venture Financing 14
PTC Therapeutics Raises US$2 Million In Venture Financing 16
Ptc Therapeutics Raises US$30 Million In Venture Financing 17
PTC Therapeutics Enters into Agreement with University of Pennsylvania 18
Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 19
Dualsystems Biotech Enters Into Agreement With PTC Therapeutics For Drug Profiling 20
PTC Therapeutics Expands Its Collaboration With Parent Project Muscular Dystrophy 21
Roche Enters Into Licensing Agreement With PTC Therapeutics And SMA Foundation 22
PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 23
AstraZeneca Enters Into Collaboration And Licensing Agreement With PTC Therapeutics 24
PTC Therapeutics Raises USD125 Million in Public Offering of Shares 25
PTC Therapeutics Completes Public Offering Of Shares For US$126.5 Million 27
PTC Therapeutics Completes IPO For US$144.4 Million 29
PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 31
Sanofi May Acquire PTC Therapeutics 33
PTC Therapeutics Inc, Key Competitors 34
PTC Therapeutics Inc, Key Employees 35
PTC Therapeutics Inc, Other Locations 36
PTC Therapeutics Inc, Subsidiaries 36

★海外企業調査レポート[PTC Therapeutics Inc (PTCT)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • ZTE Corporation：企業のM&A・事業提携・投資動向
    ZTE Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ZTE Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Innovative Med Concepts LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Innovative Med Concepts LLC (Innovative Med Concepts) is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray which is used to treat viral pharyngitis that provides relief …
  • Pfenex Inc (PFNX)：企業の財務・戦略的SWOT分析
    Summary Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company’s lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple scl …
  • Program for Appropriate Technology in Health：医療機器：M&Aディール及び事業提携情報
    Summary Program for Appropriate Technology in Health (PATH) is a non-profit organization that improves health in women and children. The organization offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. It develops diagnostics for HIV and other …
  • Minnesota Municipal Power Agency：企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • RegenxBio Inc (RGNX)：企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • TRACON Pharmaceuticals Inc (TCON)：医療機器：M&Aディール及び事業提携情報
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product …
  • The Boston Beer Co Inc (SAM)：企業の財務・戦略的SWOT分析
    The Boston Beer Co Inc (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • University of California Los Angeles-医療機器分野：企業M&A・提携分析
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, graduat …
  • Memphasys Ltd (MEM)：製品パイプライン分析
    Summary Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a bio-separations company that develops and commercializes separation techniques based on its membrane technology. The company develops felix, a non-DNA damaging lab instrument for sperm separation that separates sperm from semen samp …
  • AF Gruppen ASA (AFG)：企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Saint-Gobain Weber GmbH：企業の戦略・SWOT・財務情報
    Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report Summary Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China Mobile Limited：企業の戦略・SWOT・財務情報
    China Mobile Limited - Strategy, SWOT and Corporate Finance Report Summary China Mobile Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Midatech Pharma Plc (MTPH)：企業の財務・戦略的SWOT分析
    Summary Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company’s products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimm …
  • ZoomMed Inc (ZMD)：医療機器：M&Aディール及び事業提携情報
    Summary ZoomMed Inc (ZoomMed) is a technical service provider that offers web solutions for medical sectors. The company’s product includes ZoomMed Network, ZRx Prescriber, PraxisLab, and EvPsych. It builds and operates a clinical information exchange platform between physicians and specialists, pat …
  • Akers Biosciences Inc (AKER)：医療機器：M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • Karlsruhe Institute of Technology-製薬・医療分野：企業M&A・提携分析
    Summary Karlsruhe Institute of Technology (KIT) is an educational institute that offers research based scientific education. The institute offers research programs in the areas of biology, chemistry, and process engineering; mechanical and electrical engineering; physics and mathematics; natural and …
  • Sareum Holdings Plc (SAR)：企業の財務・戦略的SWOT分析
    Sareum Holdings Plc (SAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Community Trust Bancorp Inc：企業の戦略・SWOT・財務情報
    Community Trust Bancorp Inc - Strategy, SWOT and Corporate Finance Report Summary Community Trust Bancorp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Mitsui E&S Holdings Co., Ltd. (7003)：企業の財務・戦略的SWOT分析
    Mitsui E&S Holdings Co., Ltd. (7003) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆